Search Results
Sep 09, 2026, 12:36 ET Kaiser Permanente presents a fireside chat -- 'Tough pill to swallow: Balancing access and affordability in pharmacy'
fireside chat on Tuesday, October 6, 2026 at 10 a.m. PT, to explore the challenges and opportunities of high-cost, highly effective medications — like GLP-1s — and how value-based care systems are balancing better patient outcomes, access, and affordability.
More news about: The Permanente Federation
Sep 09, 2026, 11:02 ET Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
target antagonism, antibody constructs, and combination therapies, AI-306 is currently in IND-enabling development with cell line development underway. GLP toxicology studies are scheduled to initiate in late 2026, and an IND filing is targeted for the second quarter of 2027. Apeximmune has developed proprietary
More news about: Apeximmune
Sep 09, 2026, 10:19 ET Beyond the Scale: Orderly Wellness and Veo Health Team Up to Give GLP-1 Patients the Full Picture
access to two new Veo Health biomarker panels built for the GLP-1 journey - know more.Through the partnership, OrderlyMeds customers gain access to two new Veo Health membership tiers built for the GLP-1 journey: Veo Core (60+ biomarkers and AI-powered insights) and Veo
More news about: Veo Health
Sep 09, 2026, 09:00 ET First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA
About GZC8072 TabletsGZC8072 is a novel ultra-long-acting oral peptide GLP-1 RA independently developed by Gan&Lee based on native GLP-1 and designed for once-weekly administration. It is being developed for the treatment of type 2 diabetes mellitus
More news about: Gan & Lee Pharmaceuticals
Sep 09, 2026, 08:00 ET MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
DA-1726DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
Sep 09, 2026, 08:00 ET 1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia
agreement with 1cBio and look forward to working together to advance the program."Lee's Pharm will be responsible for Good Laboratory Practice (GLP) safety studies and manufacturing activities required to gain regulatory approval for OC-3 in China and the other Southeast Asian territories included
More news about: 1cBio, Inc.
Sep 08, 2026, 15:08 ET Hanover Foods Launches GLP-1-friendly Skinny Veg® Line
Skinny Veg® frozen vegetable product line to serve the growing market of consumers using GLP-1 weight-loss medications.
More news about: Hanover Foods Corp.
Sep 08, 2026, 12:01 ET Sara Lee® Expands Sweet Moments™ with Six New Single-Serve Desserts for Everyday Indulgence
at Sara Lee. "Smaller households, the rise of 'little treat' culture and everyday indulgence, and the growing adoption of GLP-1 medications may be changing consumer behavior for different reasons, but together they point to greater interest in smaller portions and more flexible
More news about: Sara Lee Frozen Bakery
Sep 08, 2026, 10:06 ET Amino Minder Brings Real Pharmacokinetic Modeling to Peptide and GLP-1 Tracking, Now Live on the Web -- Android App Coming Soon
aminominder.com), a peptide, GLP-1, TRT, and HRT protocol tracker built around a feature no competing app currently claims: a real pharmacokinetic (PK) engine that estimates and graphs
More news about: Amino Minder
Sep 08, 2026, 09:00 ET Doug Brown, global nutrition industry veteran, appointed as new CEO Amai Proteins
exceptional Amai Proteins team and help lead us into the next phase of growth. sweelin® is a perfect product at the right time for the GLP-1/peptide era," says Doug Brown.Amai Proteins wishes to thank its outgoing CEO, Dr. Amir Guttman for navigating the company through an intense
More news about: Amai Proteins
Sep 08, 2026, 08:30 ET FSA Day™ Returns with Major Savings, plus 16 Chances to Win Your Cart
their funds can cover—from OTC medicines, to the skin and suncare brands they love, to the hi-tech health trackers they've been eyeing, to GLP-1 treatments through Patiently™—and enjoy exceptional savings while doing so. FSA Store® will also host a Win Your Cart Sweepstakes* in the
More news about: Health-E Commerce
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralintide類似、強效的每日一次口服小分子胰澱素選擇性受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be
More news about: Ascletis Pharma Inc.
Sep 07, 2026, 00:15 ET 歌禮宣佈獲納入滬港通及深港通計劃項下的港股通名單
Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralintide類似、強效的每日一次口服小分子胰澱素選擇性受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Sep 07, 2026, 00:15 ET Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be
More news about: Ascletis Pharma Inc.
Sep 04, 2026, 06:47 ET Gan & Lee e Menarini Group collaborano per far progredire Bofanglutide in Europa
termini dell'accordo, le parti collaboreranno alla registrazione e alla commercializzazione dell'agonista del recettore del peptide-1 simil-glucagone (GLP-1 RA), bofanglutide (codice di sviluppo: GZR18),sviluppato in modo indipendente, attualmente in fase di sviluppo per il trattamento degli adulti con
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 04, 2026, 06:12 ET GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly
overview in young children of the use of GLP-1 drugs to fight the obesity epidemic in the United States and shows that while the absolute numbers of children under the age of 12 receiving GLP-1 treatment is still low, GLP-1 use is accelerating rapidly," said lead investigator
More news about: NYU Langone Health System
Sep 04, 2026, 06:02 ET 12 Top Press Releases from August
decision makers and executive leaders are focused on navigating the rising price of prescription drugs, managing access to expensive treatments such as GLP-1s, and encouraging the use of more cost-effective biosimilars.Read more of
More news about: PR Newswire
Sep 03, 2026, 17:26 ET Gan & Lee и Menarini Group сотрудничают для продвижения бофанглутида в Европе
соглашением стороны будут сотрудничать в области регистрации и коммерциализации независимо разработанного агониста рецептора глюкагоноподобного пептида-1 (GLP-1 RA) Gan & Lee, бофанглутида (код разработки: GZR18), который разрабатывается для лечения взрослых с ожирением или избыточной массой тела и вводится
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:28 ET Gan & Lee y Menarini Group se asocian para impulsar el desarrollo de bofanglutida en Europa
virtud de este acuerdo, las partes colaborarán en el registro y la comercialización del agonista del receptor del péptido similar al glucagón tipo 1 (GLP-1 RA), bofanglutida (código de desarrollo: GZR18), desarrollado de forma independiente por Gan & Lee, que se encuentra en desarrollo para el tratamiento
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:08 ET Gan & Lee a Menarini Group uzavřely partnerství k prosazení přípravku bofanglutid v Evropě
Group („Menarini"). Na základě této dohody budou strany spolupracovat na registraci a komercializaci agonisty receptoru peptidu 1 podobného glukagonu (GLP-1 RA), bofanglutidu (vývojový kód: GZR18), který společnost Gan & Lee vyvinula samostatně a který je v současné době ve vývoji pro léčbu dospělých
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:04 ET Gan & Lee und die Menarini Group schließen Partnerschaft zur Weiterentwicklung von Bofanglutide in Europa
werden die Parteien bei der Zulassung und Vermarktung des von Gan & Lee eigenständig entwickelten Glucagon-ähnlichen Peptid-1-Rezeptoragonisten (GLP-1 RA) Bofanglutide (Entwicklungscode: GZR18) zusammenarbeiten; der Wirkstoff, der derzeit zur Behandlung von Erwachsenen mit Adipositas oder Übergewicht
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:01 ET Gan & Lee et le groupe Menarini s'associent pour faire progresser le bofanglutide en Europe
l'homologation et à la commercialisation du bofanglutide (code de développement : GZR18), un agoniste du récepteur du peptide-1 similaire au glucagon (GLP-1 RA) développé de manière indépendante par Gan & Lee, et qui est actuellement en cours de développement pour le traitement de l'obésité ou du surpoids
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 12:11 ET Specialty Enzymes & Probiotics Launches SlimSEB™
all-in-one solution for holistic metabolic support," said Reshma Rathi, Vice President of Specialty Enzymes & Probiotics. "It's ideal for standalone and GLP-companion products, supporting companies that formulate clean-label, research-backed options for metabolic health."With SlimSEB™, Specialty Enzymes
More news about: Specialty Enzymes & Probiotics
Sep 03, 2026, 10:07 ET GUTS UPCOMING DEADLINE: SueWallSt Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm
stood in contrast to September 2025 statements that Revita-treated patients had lost an additional 2.5% of total body weight after stopping GLP-1 therapy.The second leg came the next day. Following post-market analyst reports, shares declined a further $0.125, or 21.37%, to $0.46 on
More news about: SueWallSt.com